Cerecor acquires global development rights to MK-0657 from Merck
The small molecule NMDA receptor subunit 2B antagonist MK-0657 will be developed against all human indications, includingdepression. Initially, Merck developed MK-0657 for the treatment of Parkinson’s disease. Cerecor
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.